PVR and neoplasm: CD155 and CD112 are mainly expressed on APCs, T cells, and tumor cells, etc. TIGIT competes with CD226 (DNAM-1) and CD96 (TACTILE) for corresponding ligands, and plays different roles: CD226 delivers a positive co-stimulatory signal, while CD96 and TIGIT deliver inhibitory signals (96).